Hints and tips:
Related Special Reports
...“AI is enabling us to not only increase the success and speed of our biologics discovery process, but also enhance the diversity of the biologics we discover,” Sapra said....
...Tony Wood, chief scientific officer of GSK, said the asthma drug could “expand the reach of our current respiratory biologics portfolio, including to the 40 per cent of severe asthma patients . . . where...
...In August, AstraZeneca signed a deal with China’s CanSino Biologics for the production of its potential mRNA vaccines....
...AstraZeneca has signed a deal with Chinese pharmaceutical company CanSino Biologics to develop potential messenger RNA vaccines, as the Anglo Swedish company expands its work to include the technology first...
...Samsung Biologics has also been on the acquisition hunt....
...Mario Gargiulo, the president of the European biologics division of Catalent, told the Financial Times that every batch shipped from Anagni had met rigorous quality specifications and testing....
...“If we don’t end up submitting it for a BLA [biologics licence application], I don’t think it will have an impact around the world.”...
...“It’s absolutely a commitment to British science, but it is also a commitment to everything we have locally here around us, the university, the hospital, the biologic centres,” he said....
...More blacklist news: Wuxi Biologics, the Chinese biotechnology group, sought to reassure investors by saying it might repurchase up to $500m in shares after worries that the US government might place it...
...Earlier this week Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research — which is responsible for assessing the vaccines — told Reuters that he would resign if the agency were...
...“Our vaccine is a ‘biologic’ product that starts with growing ‘living’ ingredients....
...That was the valuation of the specialty ingredients business of Switzerland’s Lonza, for which Bain paid $4.7bn in February. The extra funds would help fuel expansion....
...It has also struck deals for Lonza’s speciality chemicals business and the Spanish telecoms operator MasMovil, both alongside other buyout groups....
...Soriot’s, contrary to popular belief at the time, was quite good: Astra had interesting biologics and oncology prospects....
...As part of a diplomatic charm offensive, China has pledged deliveries of its four leading Covid-19 vaccines — two developed by Sinopharm, one by Beijing-based Sinovac and another from CanSino Biologics —...
...The AstraZeneca and J&J shots are both adenoviral vector vaccines — as are Russia’s Sputnik V jab and the shot developed by China’s CanSino Biologics — meaning they use an adenovirus, such as the common...
...Peter Marks, the head of the FDA’s Center for Biologics Evaluation and Research, said earlier in the week the vaccines would not expire while in storage....
...Latest news Iceland became the first European country to begin reopening its economy thanks to its low infection rate A vaccine from China's CanSino Biologics is 66 per cent effective in preventing symptomatic...
...“With biologics, it doesn’t work like that. I think the biology of it is completely overlooked by all sides.”...
...The regulation of vaccines, which are technically biologics, falls into the EMA’s remit, including for the UK, which is in a transition period as it departs the bloc....
...He cites platforms such as Cocoon from Lonza, and another from Ori Biotech, which are automating and standardising cell and gene therapy manufacturing....
...This year, says Berkley, the main limiting factor is likely to be manufacturing capacity in an industry where it is incredibly difficult to quickly ramp up supply of delicate biologics....
...Charted waters UK plc is up for sale....
...Phase-one vaccine trials conducted by Moderna of the US induced positive antibody responses, while the vaccines developed by CanSino Biologics and Pfizer and BioNTech also showed good signs of provoking...
...One of Mr Soriot’s earliest decisions was to focus on projects that had languished in the biologics division, formed as a result of the highly criticised $15bn acquisition of MedImmune in 2007....
International Edition